Medpace Holdings, Inc.

- There is no specific mention of current or future new fundraising through debt or equity in the provided transcript. - Kevin Brady (Executives) noted that the company has over $800 million in buyback authorization and will continue to execute their planning strategy. - When asked about buybacks or cash flow usage, the response indicated ongoing execution of their existing capital strategies but no explicit plans for new fundraising. - The company appears focused on internal growth, managing cancellations, and improving win rates rather than seeking new external funding at this time.

- Medpace plans to continue investing in AI and technology, but expects no net productivity benefit from AI in the near term (next 1-2 years) due to required investments offsetting gains. - AI initiatives are seen as a multi-year effort aiming for future efficiency improvements. - No specific capital expenditure figures or detailed strategic investment amounts were disclosed. - The company is focused on expanding its pipeline and improving win rates through unspecified initiatives. - Medpace continues to hire, reflecting confidence in future growth despite cancellations. - No mention of new buyback programs or major capital projects beyond existing plans.

- Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations and a sub-1 book-to-bill ratio. - Backlog coverage beyond 1 year has declined for six consecutive quarters, raising concerns about near-term sequential revenue growth. - Growth depends on either a reduction in cancellations or an increase in new awards and pipeline expansion. - Pre-backlog (future potential projects not yet started) has grown but remains variable; gross bookings are anticipated to increase, though no specific bookings guidance is given. - There is a lag of 2 to 3 quarters between booking awards and booking recognition, impacting revenue cadence. - The company anticipates continued investment in AI with no near-term productivity benefit expected before 2028. - Overall, the outlook reflects cautious optimism with challenges from cancellations and timing but an expectation for revenue growth stability.

- Medpace reconfirmed 2026 guidance for revenue, EBITDA, net income, and EPS, indicating confidence in hitting targets despite higher cancellations. - Revenue growth faces near-term pressure due to elevated cancellation rates and slower backlog growth, with sequential revenue growth uncertain. - CEO August Troendle emphasized a focus on expanding the pipeline and improving win rates to counteract cancellations and support future growth. - No specific quantification of bookings growth, but an expectation of increased bookings over time was expressed without guarantees. - AI-related productivity gains are not expected in the next 1-2 years due to required investments offsetting benefits. - CEO plans to retain his role for the foreseeable future, ensuring leadership stability. - Uncertainty remains for 2027 and beyond; sequential growth is a "real question" pending cancellation trends and new awards.

- The company distinguishes between backlog (ongoing projects with recognized bookings) and pre-backlog (authorized but not yet started projects which may never start). - Pre-backlog size is generally comparable to or somewhat larger than the backlog. - There has been growth in pre-backlog, estimated around 30%, but exact metrics are not disclosed. - Bookings to backlog conversion takes on average about 3 to 5 quarters. - Bookings recognition generally coincides with "first patient in" for clinical trials. - The current quarter showed good awards (wins) and win rates, but many projects are in pre-backlog and have not yet started. - Cancellations remain elevated, affecting backlog growth and revenue outlook. - Future bookings are expected to increase, but no specific quantitative guidance is provided. - The company acknowledges a lag of 2-3 quarters between booking awards and revenue realization.